Clinical Drug Data

The best single resource available for evaluating and comparing more than 1200 commonly-used medications 4 STAR DOODY'S REVIEW! "Although the primary audience for this book is practicing pharmacists, clinical pharmacists, pharmacy residents, and pharmacy students, the wide range of audiences who may benefit from this book include physicians and medical residents who may find this a useful resource, especially with the downloadable option....This is a useful and easy to use reference. Information is systematically organized in an easy to retrieve way."--Doody's Review Service "...will be useful to all health care professionals in a clinical setting." - Review of an earlier edition from the Australian Journal of Hospital Pharmacy Now includes PDA download of the entire text! Uniquely designed to allow comparisons within drug categories, Handbook of Clinical Drug Data is the most comprehensive, well-referenced book available on the selection, use, and clinical aspects of virtually any drug. Compiled by expert clinicians, this quick-access guide delivers the data you need to prevent adverse drug reactions in your patients and help you select drugs for both general and special patient populations Features Full-text PDA download More than 3800 literature citations Comparison charts of drugs by class facilitates clinical decision making Tables to help you rapidly identify the cause of adverse drug effects in patients Guidance on the optimal choice of drugs in special populations, including pregnant and breastfeeding women, and geriatric patients Genetic and ethic considerations Extensively cross-referenced index includes Canadian and British drug names Valuable appendices that include Conversion Factors, Anthropometrics, Laboratory Indices, Pharmacokinetic Equations, and more

The best single resource available for evaluating and comparing more than 1200 commonly-used medications 4 STAR DOODY'S REVIEW! "Although the primary audience for this book is practicing pharmacists, clinical pharmacists, pharmacy residents, and pharmacy students, the wide range of audiences who may benefit from this book include physicians and medical residents who may find this a useful resource, especially with the downloadable option....This is a useful and easy to use reference. Information is systematically organized in an easy to retrieve way."--Doody's Review Service "...will be useful to all health care professionals in a clinical setting." - Review of an earlier edition from the Australian Journal of Hospital Pharmacy Now includes PDA download of the entire text! Uniquely designed to allow comparisons within drug categories, Handbook of Clinical Drug Data is the most comprehensive, well-referenced book available on the selection, use, and clinical aspects of virtually any drug. Compiled by expert clinicians, this quick-access guide delivers the data you need to prevent adverse drug reactions in your patients and help you select drugs for both general and special patient populations Features Full-text PDA download More than 3800 literature citations Comparison charts of drugs by class facilitates clinical decision making Tables to help you rapidly identify the cause of adverse drug effects in patients Guidance on the optimal choice of drugs in special populations, including pregnant and breastfeeding women, and geriatric patients Genetic and ethic considerations Extensively cross-referenced index includes Canadian and British drug names Valuable appendices that include Conversion Factors, Anthropometrics, Laboratory Indices, Pharmacokinetic Equations, and more

This handbook, which in its early lustrous years served physicians, pharmacists, and pharmacy students, is unlike any other drug reference book in that it allows readers to compare and contrast various drugs within drug categories, thereby enabling them to make decisions on which drug to administer. All other drug reference books merely repeat the drug manufacturers' literature, with no analysis of that information. Nor are there any reports from the published literature concerning use and efficacy of the drugs listed. The clinical drug information with part II contains chapters on drug-induced diseases, drug interactions and interferences, drug use in special populations, immunization, medical emergencies, and nutrition support. There are also appendices that contain useful conversion factors, anthropometrics, and laboratory indices. Unique Features: Comprehensive comparison charts of drugs by class for easy clinical decision making Tables that help rapidly identify the cause of adverse drug effects in your patients Guides to the optimal choice of drugs in special populations, such as pregnant and breastfeeding women, renal disease, and dialysis The only referenced drug handbook--includes over 3,600 literature citations Tabbing guide for easy location of drug categories Extensive cross-referenced index that includes Canadian and British drug names

Randomized clinical trials are the primary tool for evaluating new medical interventions. Randomization provides for a fair comparison between treatment and control groups, balancing out, on average, distributions of known and unknown factors among the participants. Unfortunately, these studies often lack a substantial percentage of data. This missing data reduces the benefit provided by the randomization and introduces potential biases in the comparison of the treatment groups. Missing data can arise for a variety of reasons, including the inability or unwillingness of participants to meet appointments for evaluation. And in some studies, some or all of data collection ceases when participants discontinue study treatment. Existing guidelines for the design and conduct of clinical trials, and the analysis of the resulting data, provide only limited advice on how to handle missing data. Thus, approaches to the analysis of data with an appreciable amount of missing values tend to be ad hoc and variable. The Prevention and Treatment of Missing Data in Clinical Trials concludes that a more principled approach to design and analysis in the presence of missing data is both needed and possible. Such an approach needs to focus on two critical elements: (1) careful design and conduct to limit the amount and impact of missing data and (2) analysis that makes full use of information on all randomized participants and is based on careful attention to the assumptions about the nature of the missing data underlying estimates of treatment effects. In addition to the highest priority recommendations, the book offers more detailed recommendations on the conduct of clinical trials and techniques for analysis of trial data.

Data sharing can accelerate new discoveries by avoiding duplicative trials, stimulating new ideas for research, and enabling the maximal scientific knowledge and benefits to be gained from the efforts of clinical trial participants and investigators. At the same time, sharing clinical trial data presents risks, burdens, and challenges. These include the need to protect the privacy and honor the consent of clinical trial participants; safeguard the legitimate economic interests of sponsors; and guard against invalid secondary analyses, which could undermine trust in clinical trials or otherwise harm public health. Sharing Clinical Trial Data presents activities and strategies for the responsible sharing of clinical trial data. With the goal of increasing scientific knowledge to lead to better therapies for patients, this book identifies guiding principles and makes recommendations to maximize the benefits and minimize risks. This report offers guidance on the types of clinical trial data available at different points in the process, the points in the process at which each type of data should be shared, methods for sharing data, what groups should have access to data, and future knowledge and infrastructure needs. Responsible sharing of clinical trial data will allow other investigators to replicate published findings and carry out additional analyses, strengthen the evidence base for regulatory and clinical decisions, and increase the scientific knowledge gained from investments by the funders of clinical trials. The recommendations of Sharing Clinical Trial Data will be useful both now and well into the future as improved sharing of data leads to a stronger evidence base for treatment. This book will be of interest to stakeholders across the spectrum of research--from funders, to researchers, to journals, to physicians, and ultimately, to patients.